Member Info for Rocka

I’d be very happy if it did that, as i hold share but i don’t see it happening anytime soon!

And more sells

Someone is clearly hell bent on getting rid of these at any cost. More

Mm you’re only mocking yourself i actually feel sorry for you.

You are already at a loss from your topup today. Fantastic news😂😂

Market loves it so much its up a whopping 0.17%😂😂😂

Really Chris? Market likes it sure its up 0.17% bless u

Mm, my opinion is irrelevant, the overall market doesn’t seem to think so, hence no significant rise in SP.

Furthermore we have a massive seller who wants to get rid of their shares, thats not helping the sp!

Market is neutral on the RNS hence no rise. Nothing to do with market makers.

50% ? Should have, why? Coz you said it should?

Zero effect on the sp. Down 2% mmhater!!

Look at the 5 day , 1 month 3, 6 12 months, 1year 5y its in a decline this isnt my opinion its a FACT

It is in decline and this is a fact!! Look at the charts, stop talking nonsense.

If things are looking good the so would not be declining, the trend is down and unfortunately the Market does not agree with you at all.

Well chatgpt is wrong? Have a read, lets see what you have to say!!!

1. The Reality of the NCI CollaborationThe London Stock Exchange updates for Fusion Antibodies show exactly how the NCI agreement works, and it is not a commercial goldmine:It Is Done for "Goodwill": The company's filings explicitly state that Fusion Antibodies has been providing NCI with access to OptiMAL® on a goodwill basis to help validate the platform.No Large Revenues Yet: While Dr. Mitchell Ho's group at the NCI confirmed that the antibodies bind to cancer targets, NCI is a research institute, not a commercial buyer. They are testing the platform, but they are not writing multi-million-pound checks to purchase it.The Revenue Gap: Scientific validation can take 5 to 10 years before it ever turns into a commercial drug that generates actual profit. Fusion Antibodies only has £1.04 million in cash left right now. They do not have 5 years of cash to wait for this to become profitable.2. The Market Has Already Reacted and Moved OnYou are treating the NCI news like a secret catalyst that will push the stock up tomorrow.Old News: The initial NCI success was announced back in September 2025, causing a short-term 28% spike.The Market’s Answer: Even with the NCI updates and a new U.S. patent, the stock has steadily dropped from its peak down to 11.80p. The professional market looked at the NCI news, looked at the company's low cash, and decided to sell. Independent analysts at Investing.com UK still list the technical metrics as a "Strong Sell".

Over the last four months, the Fusion Antibodies (LON:FAB) share price has been trapped in a steady downward slide, falling from a high of 16.00p down to its current price of 11.80p.The data proves that the stock is not experiencing a healthy, temporary fluctuation; it is slowly bleeding value over time.1. The 4-Month Price BreakdownLooking at the specific monthly milestones over the last four months highlights a very clear, consistent trend:February: The stock peaked at a high of 16.00p following the January capital raise, before closing the month down around 14.00p.March: The price continued its downward slide, hitting a monthly low of 11.50p.April: A minor short-term bounce pushed the price back up toward 14.50p, but it could not sustain that momentum.May: The steady bleed resumed, forcing the price back down to 12.75p.June (Current): The stock has dropped even further, hitting an unmitigated monthly low of 11.80p.2. What this Visual Trend Teaches YouThis price chart shows a classic technical pattern called "Lower Highs and Lower Lows."Every single time the stock bounces a little bit, it fails to reach its previous peak before crashing to an even lower bottom.Relying on the hope that it "always recovers a bit" is a complete illusion. Over the medium term, the stock has lost nearly 26% of its value since February.

This RNS is a classic example of a penny stock trying to make a weak financial situation look excellent to retail investors.

Chatgpt

This is chatgpt saying this not me!! Stop trying to make excuses for Adrian!